Methylprednisolone

Methylprednisolone is a synthetic corticosteroid drug structurally related to prednisolone and hydrocortisone[1][5][7]. Its principal clinical utility is as an anti-inflammatory and immunosuppressive agent, prescribed in tablet or injectable form for a broad range of disorders involving excessive or inappropriate immune activity, such as autoimmune diseases, allergic disorders, cancer, and various other inflammatory conditions[2][3][4][8]. As a drug, methylprednisolone exerts its effects by binding to intracellular glucocorticoid receptors, modulating gene transcription and leading to decreased production of pro-inflammatory mediators and reduced immune cell activation[6][8]. Its formulation and derivatives (e.g., methylprednisolone sodium succinate, methylprednisolone acetate) allow tailored dosing for oral, intravenous, and intramuscular administration[1][8]. In summary: Methylprednisolone is a drug, not a molecular target. Its mechanism of action is via binding and activation of the glucocorticoid receptor (NR3C1), and all therapeutic effects stem from this interaction. Its incorrect classification here as a receptor or target should be noted.

Other names

MedrolSolu-MedrolDepo-Medrol6α-methylprednisolone11β,17,21-trihydroxy-6α-methylpregna-1,4-diene-3,20-dioneMethylprednisolone sodium succinateMethylprednisolone acetate

Binds to and activates glucocorticoid receptor (GR/NR3C1) - Downregulates inflammatory mediators - Suppresses immune cell function - Alters gene transcription via receptor-ligand complex